Earnings season is really shifting into high gear this week. With dozens of major companies reporting, it’s important to focus on the very best. Let’s take a look at some of the most notable IBD 50 stocks with upcoming earnings. Apple (AAPL) reports after the close on Tuesday, and its results are sure to be boosted by its iPhone 6 lineup. Up next we have Biogen (BIIB), which reports before the open on Wednesday. The biotech recently added
Biogen Idec (BIIB) put up mixed results from a midstage trial of a much-anticipated new drug Thursday, seesawing the stock in early trading. The phase-two trial deployed a drug called anti-LINGO-1, a monoclonal antibody that acts against a protein called leucine rich repeat and Ig domain containing 1 (LINGO-1), against optic neuritis, a vision impairment that’s a common side effect of multiple scleroris due to the deteriorating myelin sheath
Big-cap biotech Biogen Idec (BIIB) said Tuesday that it’s moving its drug candidate for Alzheimer’s disease into late-stage testing after promising early-stage results, sending the stock up 6% in heavy trading in the stock market today. At the Deutsche Bank BioFEST conference in Boston, Biogen executives said that results from a 194-patient phase one trial for BIIB-037, which it is jointly developing with Japan’s Eisai, were good enough to push